Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate
- PMID: 12802023
- DOI: 10.1056/NEJMoa035140
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate
Erratum in
- N Engl J Med. 2003 Sep 25;349(13):1299
-
Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate.N Engl J Med. 2024 Jul 11;391(2):192. doi: 10.1056/NEJMx240004. Epub 2024 Jun 26. N Engl J Med. 2024. PMID: 38924755 No abstract available.
Abstract
Background: Women who have had a spontaneous preterm delivery are at greatly increased risk for preterm delivery in subsequent pregnancies. The results of several small trials have suggested that 17 alpha-hydroxyprogesterone caproate (17P) may reduce the risk of preterm delivery.
Methods: We conducted a double-blind, placebo-controlled trial involving pregnant women with a documented history of spontaneous preterm delivery. Women were enrolled at 19 clinical centers at 16 to 20 weeks of gestation and randomly assigned by a central data center, in a 2:1 ratio, to receive either weekly injections of 250 mg of 17P or weekly injections of an inert oil placebo; injections were continued until delivery or to 36 weeks of gestation. The primary outcome was preterm delivery before 37 weeks of gestation. Analysis was performed according to the intention-to-treat principle.
Results: Base-line characteristics of the 310 women in the progesterone group and the 153 women in the placebo group were similar. Treatment with 17P significantly reduced the risk of delivery at less than 37 weeks of gestation (incidence, 36.3 percent in the progesterone group vs. 54.9 percent in the placebo group; relative risk, 0.66 [95 percent confidence interval, 0.54 to 0.81]), delivery at less than 35 weeks of gestation (incidence, 20.6 percent vs. 30.7 percent; relative risk, 0.67 [95 percent confidence interval, 0.48 to 0.93]), and delivery at less than 32 weeks of gestation (11.4 percent vs. 19.6 percent; relative risk, 0.58 [95 percent confidence interval, 0.37 to 0.91]). Infants of women treated with 17P had significantly lower rates of necrotizing enterocolitis, intraventricular hemorrhage, and need for supplemental oxygen.
Conclusions: Weekly injections of 17P resulted in a substantial reduction in the rate of recurrent preterm delivery among women who were at particularly high risk for preterm delivery and reduced the likelihood of several complications in their infants.
Copyright 2003 Massachusetts Medical Society
Comment in
-
Progesterone and preterm delivery--deja vu all over again.N Engl J Med. 2003 Jun 12;348(24):2453-5. doi: 10.1056/NEJMe030081. N Engl J Med. 2003. PMID: 12802032 No abstract available.
-
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.N Engl J Med. 2003 Sep 11;349(11):1087-8; author reply 1087-8. doi: 10.1056/NEJM200309113491115. N Engl J Med. 2003. PMID: 12968095 No abstract available.
-
Progesterone and preterm: seventy years of "déjà vu" or "still to be seen"?Birth. 2004 Sep;31(3):230-5. doi: 10.1111/j.0730-7659.2004.00315.x. Birth. 2004. PMID: 15330887
-
Progesterone for preterm labour.BJOG. 2016 Nov;123(12):2000. doi: 10.1111/1471-0528.13976. Epub 2016 Mar 30. BJOG. 2016. PMID: 27028883 No abstract available.
Similar articles
-
A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.N Engl J Med. 2007 Aug 2;357(5):454-61. doi: 10.1056/NEJMoa070641. N Engl J Med. 2007. PMID: 17671253 Clinical Trial.
-
17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.Am J Obstet Gynecol. 2015 Sep;213(3):364.e1-12. doi: 10.1016/j.ajog.2015.05.009. Epub 2015 May 13. Am J Obstet Gynecol. 2015. PMID: 25979614 Clinical Trial.
-
Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.Am J Obstet Gynecol. 2017 Sep;217(3):371.e1-371.e7. doi: 10.1016/j.ajog.2017.05.022. Epub 2017 May 17. Am J Obstet Gynecol. 2017. PMID: 28526452
-
Recurrent hope for the treatment of preterm delivery.Expert Opin Pharmacother. 2003 Dec;4(12):2363-6. doi: 10.1517/14656566.4.12.2363. Expert Opin Pharmacother. 2003. PMID: 14640934 Review.
-
Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.Minerva Ginecol. 2009 Oct;61(5):401-9. Minerva Ginecol. 2009. PMID: 19749671 Review.
Cited by
-
Evaluation of antenatal care quality for preterm birth prevention using an auditable scoring system: A retrospective, descriptive, longitudinal study in Sydney, Australia.Eur J Midwifery. 2024 Sep 24;8. doi: 10.18332/ejm/191993. eCollection 2024. Eur J Midwifery. 2024. PMID: 39351398 Free PMC article.
-
The Effect of Maternal Parity on Preterm Birth Risk in Women with Short Mid-Trimester Cervical Length: A Retrospective Cohort Study.J Clin Med. 2024 Aug 14;13(16):4773. doi: 10.3390/jcm13164773. J Clin Med. 2024. PMID: 39200915 Free PMC article.
-
Surrogate endpoints for neonatal outcome: A rapid review.Health Sci Rep. 2024 Aug 2;7(8):e2279. doi: 10.1002/hsr2.2279. eCollection 2024 Aug. Health Sci Rep. 2024. PMID: 39100713 Free PMC article. No abstract available.
-
Vaginal Progesterone for Pregnancy Prolongation After Arrested Preterm Labor: A Randomized Clinical Trial.JAMA Netw Open. 2024 Jul 1;7(7):e2419894. doi: 10.1001/jamanetworkopen.2024.19894. JAMA Netw Open. 2024. PMID: 38976270 Free PMC article. Clinical Trial.
-
A genome scale transcriptional regulatory model of the human placenta.Sci Adv. 2024 Jun 28;10(26):eadf3411. doi: 10.1126/sciadv.adf3411. Epub 2024 Jun 28. Sci Adv. 2024. PMID: 38941464 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- HD21410/HD/NICHD NIH HHS/United States
- HD21414/HD/NICHD NIH HHS/United States
- HD27860/HD/NICHD NIH HHS/United States
- HD27861/HD/NICHD NIH HHS/United States
- HD27869/HD/NICHD NIH HHS/United States
- HD27905/HD/NICHD NIH HHS/United States
- HD27915/HD/NICHD NIH HHS/United States
- HD27917/HD/NICHD NIH HHS/United States
- HD34116/HD/NICHD NIH HHS/United States
- HD34122/HD/NICHD NIH HHS/United States
- HD34136/HD/NICHD NIH HHS/United States
- HD34208/HD/NICHD NIH HHS/United States
- HD34210/HD/NICHD NIH HHS/United States
- HD36801/HD/NICHD NIH HHS/United States
- HD40500/HD/NICHD NIH HHS/United States
- HD40512/HD/NICHD NIH HHS/United States
- HD40544/HD/NICHD NIH HHS/United States
- HD40560/HD/NICHD NIH HHS/United States
- M01-RR-000080/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical